Related Experiment Video
Updated: Jul 16, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Targeting the RAS signaling pathway in malignant hematologic diseases
M A Morgan1, A Ganser, C W M Reuter
1Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
Current Drug Targets
|February 20, 2007
Summary
Targeting RAS signaling pathways offers new therapeutic strategies for hematologic malignancies. Novel agents inhibiting RAS post-translational modification, RAF, and MEK show promise, though their targets may extend beyond RAS itself.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Aberrant RAS signal transduction is a key driver in the pathogenesis of hematologic malignancies.
- Developing targeted therapies necessitates a deep understanding of these molecular pathways.
Purpose of the Study:
- To review novel agents targeting RAS signaling in hematologic malignancies.
- To discuss the mechanisms and potential broader targets of these agents.
Main Methods:
- Literature review of agents targeting RAS signaling pathways.
- Analysis of inhibitors for RAS post-translational modification (farnesyl transferase (FTase), geranylgeranyl transferase-I (GGTase-I), isoprenylcysteine carboxylmethyltransferase (ICMTase)), statins, bisphosphonates, and RAF/MEK inhibitors.
Main Results:
- Several novel agents targeting RAS signaling have been developed.
- Inhibitors of FTase, RAF, and MEK, while aimed at RAS, may affect other critical targets.
- RAS signaling is a common pathway in hematologic cancers.
Conclusions:
- Targeting RAS and related pathways presents a promising avenue for novel therapies in hematologic malignancies.
- Further research into the precise mechanisms of action for these agents is warranted to optimize patient treatment.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...